Physician profile
Craig Amnott
NPI 1558359786
$17,743.94
in general payments reported to CMS, 2019-2025
56 companies · $2,625 in 2025
The $2,625 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $1,852 · 2021: $2,622 · 2022: $3,244 · 2023: $3,360 · 2024: $2,873 · 2025: $2,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,819 · Education: $25.00 · Consulting Fee: $14.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,819.45 |
| Education | $25.00 |
| Consulting Fee | $14.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,468.23 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $2,316.33 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,796.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,782.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,546.74 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,143.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,014.30 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $954.10 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.21 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $380.57 | 2021-2025 | Freestyle Libre |
| Exact Sciences Corporation | $362.66 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $286.11 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $218.82 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $217.60 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $195.35 | 2020-2023 | Contrave, Onzetra Xsail, Nexletol |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Amnott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.